Drug Industry Asks FDA for Clarity in Natural Histories for Rare Disease Trials

Drug Industry Daily
The drug industry is asking the FDA for more clarity around whether or not natural histories should be included in rare disease trials—and two of the nation’s largest drug trade groups appear to be at odds over the issue.

To View This Article:


Subscribe To Drug Industry Daily